Every 8-K that ARS Pharmaceuticals, Inc. (SPRY) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SPRY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SPRY filings page.
ARS Pharmaceuticals reported second quarter 2026 total revenue of $33.7 million, up from $15.7 million a year earlier, driven by U.S. neffy net product revenue of $26.2 million and additional collaboration and supply revenue. neffy captured a 5% share of the U.S. epinephrine market for Type 1 allergies and an 8% share within field‑targeted accounts, with more than 16,000 unique prescribers in the quarter.
Total operating expenses reached $95.1 million, including $77.6 million of SG&A and $4.7 million of R&D, resulting in a net loss of $62.3 million or ($0.63) per share. Cash, cash equivalents and short‑term investments were $143.8 million as of June 30, 2026. The company plans aggregate SG&A and R&D expenses of $114–$126 million for the second half of 2026, implying more than a 40% reduction in cash‑based SG&A from the first half, and anticipates a path to cash flow breakeven by the end of 2027. ARS is also advancing its intranasal epinephrine program ARS‑2 in chronic spontaneous urticaria, with interim Phase 2b data expected in the first quarter of 2027.
ARS Pharmaceuticals, Inc. reported leadership changes effective July 15, 2026. Richard Lowenthal resigned from the Board of Directors, a step required under his employment agreement and the company’s Change in Control and Severance Benefit Plan to qualify for severance compensation.
On the same date, Chief Medical Officer Sarina Tanimoto, M.D. ceased employment under conditions constituting a termination without cause. In addition to severance described in an earlier proxy statement, the company agreed to pay one-time prorated 2026 target bonus amounts of $217,350 to Lowenthal and $111,780 to Tanimoto, contingent on the effectiveness of their releases of claims.
ARS Pharmaceuticals announced a leadership change, with current President Donn Casale appointed as Chief Executive Officer, effective immediately. He also joins the Board of Directors as a Class III director and will serve until the company’s 2029 annual meeting of stockholders.
Casale replaces Richard Lowenthal, whose employment was terminated without cause, effective immediately after notification on July 6, 2026. The filing incorporates by reference Casale’s existing biographical information previously filed with the SEC.
ARS Pharmaceuticals reported results from its 2026 Annual Meeting of Stockholders. As of April 27, 2026, 99,300,658 shares of common stock were outstanding and entitled to vote. Stockholders elected three Class III directors to serve until the 2029 annual meeting.
For the board seats, Saqib Islam received 51,588,419 votes for and 14,429,366 withheld, Phillip Schneider received 38,474,013 for and 27,543,772 withheld, and Laura Shawver received 45,149,811 for and 20,867,974 withheld. Each proposal also recorded 14,111,827 broker non-votes.
Stockholders ratified Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, with 79,465,541 votes for, 102,436 against, and 561,635 abstaining. They approved, on an advisory basis, named executive officer compensation and selected an annual frequency for future advisory pay votes.
ARS Pharmaceuticals reported strong first-quarter 2026 growth but remains loss-making as it invests heavily behind neffy. Total revenue for the quarter was $22.7 million, up from $8.0 million a year earlier, driven mainly by $17.5 million in U.S. net product revenue from neffy and additional collaboration and supply revenue.
Operating expenses rose to $82.8 million, largely from $72.2 million in selling, general and administrative costs tied to U.S. commercialization, including expanding the sales force from 106 to 148 representatives. The company posted a net loss of $60.6 million, or $0.61 per share.
ARS ended March 31, 2026 with $201.0 million in cash, cash equivalents and short-term investments, and believes this is sufficient to fund operations through cash-flow break-even. Commercially, neffy continues to gain traction with more than 28,000 prescribers, broader Medicaid coverage, and new programs such as a $199 retail cash price and a school access initiative. International approvals in Europe and Canada and a Phase 2b trial in chronic spontaneous urticaria add longer-term growth drivers.
ARS Pharmaceuticals is appointing Donn Casale as President, effective when he begins employment, which is expected on June 1, 2026. Current President and CEO Richard Lowenthal will remain Chief Executive Officer.
Casale brings more than 25 years of biopharma experience, most recently as Chief Commercial Officer at Dynavax Technologies since January 2023. Under an employment agreement dated May 12, 2026, he will receive a $575,000 annual base salary and be eligible for an annual discretionary bonus equal to 45% of base salary.
He will also receive a stock option valued at $6,000,000, with the number of shares determined using a modified Black‑Scholes price. The option will have an exercise price equal to the Grant Date Closing Price, vesting 25% after one year and monthly over the next 36 months, subject to continued employment. Casale will participate at the C‑suite (non‑CEO) level in the company’s Change in Control and Severance Benefit Plan, with certain limits on option vesting acceleration in change‑in‑control terminations during his first year.
ARS Pharmaceuticals, Inc. reported fourth quarter and full-year 2025 results and detailed the commercial rollout of its needle-free epinephrine nasal spray, neffy. For 2025, total revenue was $84.3 million, including $72.2 million in U.S. net product revenue from neffy, $9.7 million in collaboration revenue, and $2.4 million from supply agreements.
Operating expenses rose sharply as the company invested in commercialization, with selling, general and administrative costs of $230.1 million and research and development expenses of $13.2 million, leading to a full-year net loss of $171.3 million, or $1.74 per share. As of December 31, 2025, ARS held $245.0 million in cash, cash equivalents and short-term investments and reported 99,290,926 common shares outstanding.
The company highlighted neffy’s first full year of U.S. sales, progress in securing payer coverage, growing direct-to-consumer marketing, an expanded sales force planned for 2026, and continued global approvals, including in China and Australia. ARS also advanced its intranasal epinephrine program into a Phase 2b trial for chronic spontaneous urticaria, with interim data expected in the second half of 2026.
ARS Pharmaceuticals (SPRY) furnished an 8-K announcing financial results for the quarter ended September 30, 2025. The company issued a press release attached as Exhibit 99.1 and updated its investor presentation attached as Exhibit 99.2.
Both exhibits are furnished, not filed, under Items 2.02 and 7.01, meaning they are not subject to Section 18 liability and are not incorporated into other filings except by specific reference. SPRY’s common stock trades on The Nasdaq Stock Market LLC.
ARS Pharmaceuticals entered a credit agreement dated September 29, 2025, establishing multiple tranche term loans and customary security arrangements. The agreement allows a Term C Loan of $25.0 million that the borrower may draw before the two‑year anniversary if it achieves trailing 12‑month net revenues of at least $100.0 million. A Term D Loan of up to $100.0 million is available on an uncommitted, lender‑consent basis. The Term Loans mature five years after closing and are secured by the credit parties under a security and pledge agreement. The borrower will pay customary fees including upfront, administration, repayment premium and an exit fee, and interest on any paid‑in‑kind portion will carry a 1.00% per annum premium.
ARS Pharmaceuticals received a notice that Lupin submitted an Abbreviated New Drug Application (ANDA) seeking approval to commercially manufacture, use, or sell a generic version of neffy 2 mg (epinephrine nasal spray). The notice alleges that multiple U.S. patents listed in the FDA Orange Book for neffy (including U.S. Patent Nos. 10,576,156 and 10,682,414, among others) are invalid, unenforceable, or not infringed by the proposed generic. The filing notes ARS previously successfully defended U.S. Patent No. 10,682,414 in an Inter Partes Review. ARS states it is not aware of other ANDA filers as of this filing date.
ARS Pharmaceuticals, Inc. announced its financial results for the quarter ended June 30, 2025 via a press release attached to this Form 8-K as Exhibit 99.1. The company states that the press release is furnished and expressly not "filed" for purposes of the Exchange Act, and therefore is not incorporated by reference into other filings. The filing also confirms that ARS is an emerging growth company and that its common stock trades on The Nasdaq Stock Market under the symbol SPRY.
The company also updated its corporate investor presentation, which is available on the company website and is attached as Exhibit 99.2. The 8-K repeats that the presentation is furnished and not deemed filed, and lists the exhibits including the Interactive Data File Cover Page as Exhibit 104.
ARS Pharmaceuticals (Nasdaq: SPRY) filed an 8-K disclosing the voting results of its 2025 Annual Meeting held on June 25, 2025.
- All four Class II director nominees—Richard Lowenthal, Peter Kolchinsky, Brenton Saunders and Peter Thompson—were elected to serve until the 2028 meeting.
- Shareholders ratified Ernst & Young LLP as independent auditor for fiscal 2025 with 77,258,380 votes for (≈99.5%).
No other proposals were considered and the disclosure contains no material changes to strategy, operations or financial outlook.